Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. J.Molner AS's Free Cash Flow for the
six
months ended in Dec. 2025 was €-1.18 Mil. J.Molner AS's Revenue for the
six
months ended in Dec. 2025 was €0.60 Mil. Therefore, J.Molner AS's FCF Margin % for the quarter that ended in Dec. 2025 was -197.48%.
The historical data trend for J.Molner AS's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OTSE:MOLNR vs ZTS, UTHR, VTRS: FCF Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, J.Molner AS's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
J.Molner AS FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, J.Molner AS's FCF Margin % distribution charts can be found below:
* The bar in red indicates where J.Molner AS's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
J.Molner AS (OTSE:MOLNR) has a FCF Margin % of -197.48% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on J.Molner AS and its competitors. According to the industry distribution chart, J.Molner AS ranks #905 out of 961 companies in the Drug Manufacturers industry, placing it in the top 94.2%.
Is J.Molner AS's FCF Margin % too high?
J.Molner AS's current FCF Margin % is -197.48%. Based on the distribution chart, J.Molner AS ranks #905 out of 961 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, J.Molner AS has a GF Score™ of 40/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does J.Molner AS's FCF Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, J.Molner AS ranks #905 out of 961 companies for FCF Margin %. This places J.Molner AS in the lower half of its industry. The industry median FCF Margin % is 2.55. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.55, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on J.Molner AS and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. J.Molner AS's current FCF Margin % is -197.48%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is J.Molner AS stock overvalued right now?
Based on GuruFocus' analysis, J.Molner AS (OTSE:MOLNR) is currently considered Fairly Valued. The stock's GF Value™ is €19.62, compared to a current price of €18.90 — trading 3.7% below its estimated fair value. The current FCF Margin % is -197.48%. J.Molner AS's overall GF Score™ is 40/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For J.Molner AS (OTSE:MOLNR), the current FCF Margin % is -197.48% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is J.Molner AS (OTSE:MOLNR) Overvalued in 2026?
Based on GuruFocus' analysis, J.Molner AS stock appears to be undervalued.
The current stock price of €18.90 is trading 3.7% below its estimated GF Value™ of €19.62.
GuruFocus considers J.Molner AS to be Fairly Valued.
Key valuation signals for OTSE:MOLNR:
FCF Margin %: -197.48%
GF Value™: €19.62 vs. price of €18.90 (3.7% below fair value)
No single metric tells the full story. See the OTSE:MOLNR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
J.Molner AS is an Estonia-based company engaged in research and development in the field of biotechnology. It is developing a portfolio of generic drug products for the United States and Canadian markets, consisting of both in-house developed medicines and acquired and in-licensed products. It operates through two complementary business units: internal generic drug development and specialized pharmaceutical services. It develops and commercializes sterile injectable, ophthalmic, and dermatology generic drugs, while also providing drug development services, analytical chemistry and stability testing. Its activities are divided into two business segments, Generic Drugs and Services, with Services generating maximum revenue. The Company generates maximum revenue from the United States.
40GF Score
Get the complete analysis for OTSE:MOLNR
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OTSE:MOLNR has been successfully added to your 
